anti-coronavirus antibodies / A.O. Ospedale Papa Giovanni XXIII - LARVOL DELTA

Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients (clinicaltrials.gov) - P=N/A | N=9 | Terminated | Sponsor: A.O. Ospedale Papa Giovanni XXIII | Trial completion date: Aug 2020 ➔ Oct 2022 | Unknown status ➔ Terminated; The study was closed prematurely because the hyperimmune plasma have expired

Trial completion date • Trial termination • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients (clinicaltrials.gov) - P=N/A; N=10; Recruiting; Sponsor: A.O. Ospedale Papa Giovanni XXIII; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients (clinicaltrials.gov) - P=N/A; N=10; Not yet recruiting; Sponsor: A.O. Ospedale Papa Giovanni XXIII

Clinical • New trial • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases